MKK4启动子多态-1304T→G对结直肠癌辅助化疗预后的影响

Impact of-1304T→G polymorphism in MKK4 promoter on prognosis of colorectal cancer cases receiving adjuvant cheomotherapy

目的：分析MKK4启动子多态rs3826392位点对结直肠癌辅助化疗预后的影响。方法：回顾性分析203例结直肠癌并接受FOLFOX6辅助化疗患者rs3826392基因型与临床病理因素、总生存（overall survival,OS）、无病生存（disease free survival,DFS）的相关性。结果 ：rs3826392基因型与临床病理因素无明显相关（P〉0.05）,TG＋GG基因型相对于TT基因型,有更好的OS（P=0.018）、DFS（P=0.019）。Cox多因素分析rs3826392TG＋GG基因型是影响OS（HR=0.389;95%CI=0.177~0.855）、DFS（HR=0.491;95%CI=0.271~0.890）的独立有利因素。结论：rs3826392变异基因型（TG＋GG）可以成为结直肠癌辅助化疗良好预后的生物标记。

Objective To analyze the impact of rs3826392 polymorphism in MKK4 promoter on prognosis of colorectal cancer cases（CRC） receiving adjuvant chemotherapy. Methods The associations between rs3826392 genotype of 203 CRC cases receiving adjuvant chemotherapy and clinicopathologic factors,overall survival（OS）,disease free survival（DFS） were analyzed retrospectively. Results No association was found between rs3826392 genotype and clinicopathologic factors（P〉0.05）. TG ＋GG genotype had better OS（P = 0.018） and DFS（P =0.019） when compared with TT genotype. Cox multivariate model showed rs3826392 TG＋GG genotype remained independent favorable factor for OS（HR = 0.389;95%CI = 0.177-0.855） and DFS（HR=0.491;95%CI = 0.271-0.890） respectively. Conclusion-1304 G variant genotypes（i.e., TG＋GG） in rs3826392 may be the biomarker of better prognosis in CRC receiving adjuvant chemotherapy.